Vimta Labs Limited has informed the Exchange about Investor Presentation
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vimta Labs shared its Q1 FY26 investor presentation. Total income rose 31.4% sequentially to ₹993 Mn, though YoY growth was modest at 3.4%. EBITDA came in at ₹354 Mn with a healthy 35.7% margin, while PAT grew 3.1% YoY and 35.9% QoQ to ₹189 Mn, translating to a 19.0% PAT margin and EPS of ₹4.2. The company is nearly debt-free with a debt-to-equity ratio of 0.02 and ₹150 Mn in cash, while promoters hold 36.7% of shares and the market cap stands at roughly ₹2,001 Cr. Vimta holds the #1 position in India for pharma analytical and food testing and operates 10 labs across 600,000+ sq ft, with strategy focused on capacity expansion, service innovation, and deeper customer partnerships. The deck includes market opportunity sizing and a track record of ~25% revenue CAGR over FY20–FY25, but does not lay out specific forward financial targets.
For investors, this is a steady-state update on a profitable, low-leverage business with strong #1/#2 positioning in niche testing segments. The absence of explicit multiyear guidance on revenue, margins, or order pipeline may cap near-term stock excitement despite healthy sequential performance.